Quinazoline Derivatives Useful as CB-1 Inverse Agonists
申请人:Janssen Pharmaceutica NV
公开号:US20160068512A1
公开(公告)日:2016-03-10
The present invention is directed to quinazoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.